Search

Volta Medical announced a Joint Development Agreement with GE HealthCare. Through this collaboration, Volta aims to integrate its latest AI solution, the Volta AF-Xplorer, with GE HealthCare's latest digital platform, [...]

Pulse Biosciences announced that it has received the Breakthrough Device Designation from the FDA for the company's Cardiac Surgery System for the ablation of cardiac tissue for the treatment of [...]

Citi maintains a Buy rating on iRhythm Technologies (IRTC) after Apple (AAPL) on Friday announced FDA approval of an atrial fibrillation detection tool within its Apple Watch under the Medical [...]

Byline: Special to the RBJ In the vast symphony of life, where each moment is a precious beat, there lurks a rhythm disorder that silently affects millions, yet remains unnoticed [...]

Pulse Biosciences announced a collaboration with CardioNXT, to support Pulse Biosciences' planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation. 'We are excited to announce this [...]

Boston Scientific has received FDA approval for the latest-generation Watchman FLX Pro Left Atrial Appendage Closure Device. Designed to further advance the procedural performance and safety of the WATCHMAN technology, [...]

Cadrenal Therapeutics cited recent data that underscores additional need for an improved Vitamin K Antagonist, VKA. The Company believes tecarfarin is the solution for this unmet need. At the recent [...]

SAN DIEGO -- Local medical tech creator Vektor Medical announced it secured $16 million in Series A funding to advance its FDA-cleared, non-invasive, AI-based arrhythmia analysis platform known as vMap. [...]

A patent application by inventors from Boston Scientific Scimed Inc. describes an occlusive medical device with sensing capabilities for treating atrial fibrillation. The device aims to prevent blood clots in the left atrial appendage, reducing the risk of stroke or heart attack. The device includes an expandable framework, occlusive member, and sensors to monitor thrombus formation within the left atrial appendage. This innovation addresses the need for improved medical devices to manage atrial fibrillation in patients. [Extracted from the article]

A patent has been issued for a left atrial appendage occluder and occlusion system by Shanghai Microport Cardioadvent Co. Ltd. The invention aims to improve the re-positioning, release, and retrieval of the occluder, enhancing surgical success rates. The occluder design includes an occluding stent, proximal and distal securing members, and a traction structure, allowing for easy deployment and retrieval without the need for a snare. This innovation addresses the limitations of existing occluders and aims to improve the efficiency and success of left atrial appendage occlusion procedures. [Extracted from the article]

Researchers at Celon Pharma Inc. conducted studies to assess the bioequivalence of two forms of rivaroxaban, an oral anticoagulant and factor Xa inhibitor. The studies compared Zarixa hard capsules to Xarelto film-coated tablets in healthy White volunteers. Results showed that both products were bioequivalent and well-tolerated, with no serious adverse events reported. This research provides valuable insights for pharmaceutical companies and healthcare professionals working with factor Xa inhibitors. [Extracted from the article]

A patent has been issued for a chemical ablation apparatus developed by Suzhou Sinus Medical Technologies Co. Ltd. The apparatus is designed to treat arrhythmia, specifically atrial fibrillation (AF) and ventricular tachycardia (VT) and ventricular fibrillation (VF). The apparatus includes a clipping component, a needle head component, pipeline components, and an electrocardiographic mapping component. It aims to provide a more effective and cost-efficient treatment option for atrial fibrillation and other arrhythmias. The patent provides detailed descriptions of the apparatus and its components, as well as various claims related to its design and functionality. [Extracted from the article]

A patent has been issued for a catheter with a stacked spine electrode assembly. The catheter is designed to treat cardiac arrhythmia by mapping the electrical properties of the heart and selectively ablating cardiac tissue. The electrode array of the catheter has a simplified construction for improved manufacturability and can accommodate complex electrode arrays for greater electrode density and tissue contact. The patent provides detailed descriptions of the catheter's design and features. [Extracted from the article]

A new article in the Cardiovascular Innovations and Applications journal explores the role of chemokines in the development of atrial fibrillation (AF), a common cardiac rhythm condition. Chemokines are small proteins that communicate through specific receptors on cell surfaces. The article highlights the association between elevated levels of certain chemokines, such as CXCL8, CXCR2, CXCL12, and CXCR4, and increased atrial remodeling, prolonged hospital stays, and higher risk of death in patients with AF. The findings suggest that chemokines may play a role in the pathophysiology of AF and could be potential targets for prevention and treatment. [Extracted from the article]

Ventrimend Inc. has been issued a patent for an implantable device that can treat atrial fibrillation (AF) and prevent blood clots from forming in the left atrial appendage (LAA). AF is a heart arrhythmia that can lead to blood clots, strokes, and other complications. The device consists of an anchoring portion, a barrier element to cover the LAA, and a cardiac monitoring element. It provides an alternative treatment for patients who cannot take anticoagulant medications like warfarin. The device aims to reduce the risk of stroke while treating the arrhythmia. [Extracted from the article]

Biosense Webster (Israel) Ltd. has been issued a patent for a catheter with a high-density electrode spine array. The catheter is designed for mapping and ablating tissue surfaces in the heart, specifically the atria or ventricles. It features a distal electrode matrix with multiple spines and electrodes arranged in a grid formation, allowing for high-density mapping signals. The catheter can be deflected and dragged across the tissue surface, maintaining the spacing and configuration of the electrodes. This invention aims to improve the treatment of cardiac arrhythmias by providing more accurate and efficient mapping and ablation procedures. [Extracted from the article]

A patent application titled "Device For Left Atrial Appendage" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors James M. Anderson, Joshua Mark Inouye, and Jerry Wang, is assigned to Boston Scientific Scimed Inc. The application describes a left atrial appendage closure (LAAC) device that includes an expandable member and a covering to accommodate changes in the expandable member. The device aims to address the issue of blood clot formation in the left atrial appendage, which can lead to stroke or heart attack in patients with atrial fibrillation. [Extracted from the article]

A patent has been issued to Boston Scientific Scimed Inc. for an occlusive medical device with a sealing member. The device is designed to address the issue of thrombus formation in the left atrial appendage of patients with atrial fibrillation. The device includes an expandable framework, an occlusive member, and sealing members made from fabric. The patent provides detailed descriptions and claims for the device. This information is useful for researchers studying cardiac arrhythmias and medical device companies in the healthcare technology industry. [Extracted from the article]

A patent has been issued to Biosense Webster (Israel) Ltd. for a system that visualizes multiple parameters overlaid on an anatomical map. The system includes a processor and a display, with the processor receiving datasets corresponding to different properties of an organ and assigning visual attributes to each property. The display then shows a map of the organ with the overlaid visual attributes. The invention is particularly useful in cardiology and can be applied to properties such as voltage, local activation time, cycle length of atrial fibrillation, and standard deviation of cycle length. [Extracted from the article]

A patent has been issued for a system and method for treating tissue with pulsed field ablation. The patent addresses the challenges faced in cardiac surgery when using intravascular or percutaneous techniques, which lack direct visual contact with medical devices. The proposed system aims to improve safety, efficiency, and effectiveness by delivering high voltage pulses with shorter rise times and utilizing capacitors and a controller system. It seeks to enhance precision and area of treatment while minimizing complications and undesired physiological effects. The patent was filed by Gerald Floyd Cummings on August 11, 2021, and published on September 3, 2024. [Extracted from the article]

A patent has been issued to 460Medical Inc. for systems and methods for optical interrogation of ablation lesions. The patent describes a system that uses a catheter with electrodes and optical fibers to deliver ablation energy to tissue and monitor the tissue's response. The system aims to improve the success rate of atrial fibrillation ablation procedures by forming and verifying ablation lesions more effectively. The patent also discusses the public health burden of atrial fibrillation and the need for improved treatment options. [Extracted from the article]